search
Back to results

Goal-directed De-escalation in ARDS

Primary Purpose

ARDS, Human, Sepsis, Severe

Status
Unknown status
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Goal directed de-escalation therapy
Sponsored by
Northern State Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ARDS, Human focused on measuring de-escalation therapy, acute respiratory distress syndrome, extravascular lung water, global end-diastolic volume, sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The presence of sepsis ( the third international definition of sepsis and septic shock )
  • The precence of ARDS (the Berlin definition of ARDS)
  • mechanical ventilation before the study for at least 24 hrs
  • the age of the patient > 18 years.

Exclusion Criteria:

  • continuous infusion of norepinephrine in a dose exceeding 0.4 mcg/kg/min to maintain mean arterial pressure (MAP) within 65-75 mm Hg,
  • morbid obesity with BMI > 40 kg/m2,
  • severe brain injury,
  • chronic kidney diseases,
  • pregnancy,
  • known irreversible underlying conditions such as end-stage neoplasms.

Sites / Locations

  • City Hospital # 1 n.a. E.E. Volosevich

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

GEDVI-oriented de-escalation

EVLWI-oriented de-escalation

Arm Description

Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL

Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL

Outcomes

Primary Outcome Measures

Improvement of organ function
To assess if ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the SOFA scale by more than 20% in comparison with baseline values.

Secondary Outcome Measures

Influence on mortality
The secondary endpoint was to evaluate whether ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the 28-days mortality

Full Information

First Posted
August 5, 2020
Last Updated
August 7, 2020
Sponsor
Northern State Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04508296
Brief Title
Goal-directed De-escalation in ARDS
Official Title
De-escalation Fluid Management Guided by Volumetric Parameters in Patients With Sepsis and ARDS
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 2016 (Actual)
Primary Completion Date
December 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northern State Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Objective: To compare two de-escalation strategies guided by either extravascular lung water or global end-diastolic volume-oriented algorithms in patients with sepsis and ARDS. Design: A prospective randomized study. Setting: City Hospital #1 of Arkhangelsk, Russia, mixed ICU. Patients: Sixty patients with sepsis and ARDS were randomized to receive de-escalation fluid therapy, guided either by extravascular lung water index (EVLWI, n = 30) or global end-diastolic volume index (GEDVI, n = 30). Intervention: In case of GEDVI > 650 mL/m2 or EVLWI > 10 mL/kg, diuretics and/or controlled ultrafiltration were administered. The primary goal of de-escalation was to achieve the cumulative 48-hr fluid balance in the range of 0 to - 3000 mL. If GEDVI < 650 mL/m2 or EVLWI < 10 mL/kg, the target fluid balance was set from 0 to +3000 mL.
Detailed Description
In all patients, investigators catheterized the internal jugular or the subclavian vein with a triple-lumen central venous catheter (Certofix, B|Braun, Germany) and the femoral artery with a thermistor-tipped arterial catheter (5F, PV2015L20, Pulsion Medical Systems, Munich, Germany). The arterial blood pressure was recorded from a side port of the catheter. Hemodynamic monitoring was carried out using the method of transpulmonary thermodilution (PiCCO2 monitor, Pulsion Medical Systems, Germany) by a triplicate 15 mL bolus of cold (< 8 °C) 0.9% saline solution. Mechanical ventilation (Puritan Bennett 840 and 980, Medtronic, USA) was performed according to the ARDS Network protocol, using pressure-controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight, with a Ppeak not exceeding 35 cm H2O, positive end-expiratory pressure (PEEP) and a fraction of inspiratory oxygen (FiO2) levels adjusted to maintain SpO2 within a 92-97% range. The target fluid balance was achieved by continuous infusion of furosemide with an initial dose of 0.07 mcg/kg/hr and a minimal duration of 12 hrs. In case of failure to reach a negative fluid balance by means of diuretics, started controlled ultrafiltration using continuous veno-venous hemofiltration (CVVH, multiFiltrate, Fresenius Medical Care, Germany). For fluid replacement, if necessary, investigators administered balanced crystalloid solutions (Sterofundin Iso/G5, B|Braun, Germany) with an initial infusion rate of 6-7 ml/kg/hr. Heart rate (HR), MAP, cardiac index (CI), GEDVI, EVLWI, pulmonary vascular permeability index (PVPI), central venous pressure (CVP), systemic vascular resistance index (SVRI), pulse pressure variation (PPV), and stroke volume variation (SVV) were assessed using transpulmonary thermodilution and arterial pulse contour analysis. During the study, investigators also assessed blood gases (ABL Flex 800 Radiometer, Denmark) and biochemical parameters (Random Access A-25, BioSystems, Spain). All measurements were performed at baseline, at 24 and at 48 hrs of the goal-directed de-escalation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ARDS, Human, Sepsis, Severe
Keywords
de-escalation therapy, acute respiratory distress syndrome, extravascular lung water, global end-diastolic volume, sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GEDVI-oriented de-escalation
Arm Type
Experimental
Arm Description
Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
Arm Title
EVLWI-oriented de-escalation
Arm Type
Experimental
Arm Description
Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL
Intervention Type
Diagnostic Test
Intervention Name(s)
Goal directed de-escalation therapy
Intervention Description
Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI > 650 mL/m2 or EVLWI > 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 or EVLWI < 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
Primary Outcome Measure Information:
Title
Improvement of organ function
Description
To assess if ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the SOFA scale by more than 20% in comparison with baseline values.
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Influence on mortality
Description
The secondary endpoint was to evaluate whether ELWI- or GEDVI-oriented goal-directed therapy can lead to the decrement of the 28-days mortality
Time Frame
28-day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The presence of sepsis ( the third international definition of sepsis and septic shock ) The precence of ARDS (the Berlin definition of ARDS) mechanical ventilation before the study for at least 24 hrs the age of the patient > 18 years. Exclusion Criteria: continuous infusion of norepinephrine in a dose exceeding 0.4 mcg/kg/min to maintain mean arterial pressure (MAP) within 65-75 mm Hg, morbid obesity with BMI > 40 kg/m2, severe brain injury, chronic kidney diseases, pregnancy, known irreversible underlying conditions such as end-stage neoplasms.
Facility Information:
Facility Name
City Hospital # 1 n.a. E.E. Volosevich
City
Arkhangelsk
ZIP/Postal Code
163000
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Goal-directed De-escalation in ARDS

We'll reach out to this number within 24 hrs